.png){kind=icon}
Bioavailability, bioequivalence and biosimilars modeling
Metabolism, Bioanalysis, IChem
Neutralizing antibody (nAb) development
Record Type:Analysis
Neutralizing antibodies (NAb) occurs when a protein-based biological therapy evokes an adverse immune response. NAbs bind to therapeutic products, diminishing the intended biological function and negatively impacting the therapy efficacy and safety profile in vivo.
Cell-based NAb assays (assessing intracellular signaling events, direct or indirect) are commonly used for NAb detection, as they mimic the in vivo mechanisms more closely than non-cell-based NAb assays.
About our nonclinical animal research models: We provide the utmost care for our research animals and actively pursue advances in animal welfare. As well as ensuring the highest scientific, ethical and regulatory standards, selection of appropriate animal research models for development research is critical to developing safe and effective treatments, devices and products that protect and save lives. Just as we have ethical committee oversight for human trials, we have ethical committees overseeing all aspects of our global animal care and use programs. All of our core, nonclinical facilities are accredited by AAALAC.Learn more about our commitment to replacing, reusing and refining nonclinical research models.